{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:50:08Z","timestamp":1793346608899,"version":"4.5.0"},"reference-count":43,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shenyang Science and Technology Program","award":["20-205-4-090"],"award-info":[{"award-number":["20-205-4-090"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Objective: We performed a systematic review and meta-analysis of the efficacy and safety of nusinersen and risdiplam in the treatment of spinal muscular disease (SMA). Methods: We screened the literature published in Pubmed, Web of Science, Embase, and Cochrane before July 2023 to conduct randomized controlled trials to test the treatment of SMA patients with nusinersen and risdiplam. The data were analyzed using Review Manager 5.4 software and Stata version 15.0 software. Results: A total of six randomized controlled trials were included, involving 728 SMA patients, to synthesize evidence. It is reported that nusinersen treatment was beneficial for increasing the score of the Hammersmith Functional Motor Scale\u2014Expanded (HFMSE) (WMD: 4.90; 95% CI: 3.17, 6.63; p &lt; 0.00001), Revised Upper Limb Module (RULM) (WMD: 3.70; 95% CI: 3.30, 4.10; p &lt; 0.00001), and Hammersmith Infant Neurological Evaluation Section 2 (HINE-2) (WMD: 5.21; 95% CI: 4.83, 5.60; p &lt; 0.00001). In addition, the risdiplam treatment group also showed statistically significant improvements in the HFMSE score (WMD:0.87; 95% CI: 0.05, 1.68; p = 0.04), the 32-item Motor Function Measure (MFM32) (WMD:1.48; 95% CI: 0.58, 2.38; p = 0.001), and (WMD: 1.29; 95% CI: 0.57, 2.01; p = 0.0005). Nusinersen and risdiplam did not cause a statistically significant increase in the RULM score for adverse events (OR: 0.93; 95% CI: 0.51, 1.7; p = 0.82) and for severe adverse events (OR: 0.77; 95% CI: 0.47, 1.27; p = 0.31). Conclusion: Our analysis found that nusinersen and risdiplam treatment showed clinically meaningful improvement in motor function and a similar incidence rate of adverse events compared with the placebo. Further research should be carried out to provide a direct comparison between the two drugs in terms of safety and efficacy.<\/jats:p>","DOI":"10.3390\/brainsci13101419","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T14:03:03Z","timestamp":1696687383000},"page":"1419","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"13","author":[{"given":"Yue","family":"Qiao","sequence":"first","affiliation":[{"name":"Department of Neurology, Shengjing Hospital of China Medical University, Shenyang 110055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewei","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shengjing Hospital of China Medical University, Shenyang 110055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shengjing Hospital of China Medical University, Shenyang 110055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shengjing Hospital of China Medical University, Shenyang 110055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: Diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s10897-016-9955-8","article-title":"A Review on Spinal Muscular Atrophy: Awareness, Knowledge, and Attitudes","volume":"25","author":"Moultrie","year":"2016","journal-title":"J. Genet. Couns."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/GIM.0b013e3181c5e713","article-title":"Perspectives and diagnostic considerations in spinal muscular atrophy","volume":"12","author":"Prior","year":"2010","journal-title":"Genet. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1523\/JNEUROSCI.0417-15.2015","article-title":"Disease mechanisms and therapeutic approaches in spinal muscular atrophy","volume":"35","author":"Tisdale","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_7","first-page":"443","article-title":"Childhood spinal muscular atrophy: Controversies and challenges, The Lancet","volume":"11","author":"Mercuri","year":"2012","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3233\/JND-200534","article-title":"Measuring Outcomes in Adults with Spinal Muscular Atrophy\u2014Challenges and Future Directions \u2014Meeting Report","volume":"7","author":"Sansone","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_9","first-page":"437","article-title":"Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy","volume":"26","author":"Naveed","year":"2021","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: Promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nat. Rev. Neurol"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-319-89689-2_2","article-title":"Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes","volume":"20","author":"Singh","year":"2018","journal-title":"Adv. Neurobiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3174\/ajnr.A5596","article-title":"Transforaminal Lumbar Puncture: An Alternative Technique in Patients with Challenging Access","volume":"39","author":"Nascene","year":"2018","journal-title":"Am. J. Neuroradiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Samulski","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/acn3.51239","article-title":"Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy","volume":"8","author":"Sergott","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: First approval;PMID: 33044711","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense Oligonucleotide Therapies for Neurodegenerative Diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.4155\/fmc-2019-0239","article-title":"More is needed to complement the available therapies of spinal muscular atrophy","volume":"11","author":"Singh","year":"2019","journal-title":"Future Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"A Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_24","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/ene.15499","article-title":"Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment","volume":"30","author":"Mercuri","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Abbas, K.S., Eltaras, M.M., El-Shahat, N.A., Abdelazeem, B., Shaqfeh, M., and Bra\u0161i\u0107, J.R. (2022). The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina, 58.","DOI":"10.3390\/medicina58020213"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","article-title":"Nusinersen in Adults with 5q Spinal Muscular Atrophy: A Systematic Review and Meta-analysis","volume":"19","author":"Gavriilaki","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: A critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"Glanzman","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: Development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40120-020-00206-3","article-title":"Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy","volume":"9","author":"Trundell","year":"2020","journal-title":"Neurol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"120059","DOI":"10.1016\/j.jns.2021.120059","article-title":"Development of the SMA independence scale-upper limb module (SMAIS-ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA","volume":"432","author":"Trundell","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mus.25705","article-title":"Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study","volume":"57","author":"Bishop","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/gt.2017.52","article-title":"The clinical landscape for SMA in a new therapeutic era","volume":"24","author":"Talbot","year":"2017","journal-title":"Gene Therapy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/gt.2017.45","article-title":"Therapeutic approaches for spinal muscular atrophy (SMA)","volume":"24","author":"Scoto","year":"2017","journal-title":"Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","article-title":"Muscle strength and motor function in adolescents and adults with spinal muscular atrophy","volume":"95","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s13760-022-02028-6","article-title":"Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: A systematic review","volume":"123","author":"Gavriilaki","year":"2023","journal-title":"Acta Neurol. Belg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/jnnp-2020-324532","article-title":"Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions","volume":"92","author":"Chan","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Yang, H., Tao, Q., Li, D., Yang, J., Cai, Q., Gan, J., Huang, S., and Luo, R. (2023). Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: A retrospective study. BMC Neurol., 23.","DOI":"10.1186\/s12883-023-03063-3"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/10\/1419\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:02:15Z","timestamp":1760130135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/10\/1419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["brainsci13101419"],"URL":"https:\/\/doi.org\/10.3390\/brainsci13101419","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,7]]}}}